Clinical Trials Logo

Clinical Trial Summary

Background:

- The Lung Cancer section of the National Cancer Institute s Medical Oncology Branch is running a study to better understand which genes might be important in patients who are undergoing therapy for lung cancer.

Objectives:

- To find out if differences (also called polymorphisms) in specific genes lead to differences in outcomes (such as treatment success and survival rates) for patients who have been diagnosed with lung cancer.

- To establish a repository of genetic information for future studies of these differences and their relation to lung cancer.

Eligibility:

- Any individual who has been diagnosed with lung cancer and is being treated through the National Cancer Institute.

Design:

- After entrance in this study, patients will provide information to the researchers on age, gender, race/ethnicity, treatments received and response to treatments, and other specific information about their disease. This information will be kept confidential.

- Approximately half a tablespoon of blood will be drawn.

- Patients will be treated for lung cancer with normal treatment methods, as if they had not been enrolled in the study

- Some patients may be offered the option of enrolling in separate research protocols for cancer treatment, involving chemotherapy, surgery, or radiation.


Clinical Trial Description

Background:

- Lung cancer is the leading cause of cancer deaths among men and women worldwide.

- Despite modern surgical, radiation, and chemotherapeutic interventions, the prognosis for patients with lung cancer remains poor, with an overall cure rate of less than 15%.

- Genetic polymorphisms in drug-metabolizing enzymes, transporters, growth factor and hormonal receptors, DNA repair enzymes, and transcription factors might affect an individual s response to chemotherapy and radiation.

- Interindividual differences in efficacy and toxicity of cancer chemotherapy and radiation are especially important given the narrow therapeutic index of these modalities.

- Many of these differences have not been extensively explored in patients with lung cancer.

Objectives:

- To better understand the genotype-phenotype relationship between genetic polymorphisms and clinical outcomes, with a focus on overall survival, following lung cancer therapy.

- To better understand differences in outcome between Caucasian and African American patients being treated for lung cancer as a function of genotype.

- To establish a DNA repository for the investigation of polymorphisms related to outcomes in lung cancer.

- To develop methodology for the isolation, enumeration and live cell culture of circulating tumor cells (CTC) from lung cancer patients with microfiltration devices.

Eligibility:

- All individuals with the diagnosis of lung cancer being treated at the Washington D.C. Veterans Affairs Medical Center or the Medical Oncology Branch of the National Cancer Institute (NCI).

Design:

- A single 7-ml sample of venous blood will be obtained from all patients enrolled onto this study, for isolation of DNA.

- Two 5 ml samples of venous blood, drawn immediately following the 7 ml sample, will be obtained from all patients enrolled on this study at the NCI Clinical Center (only), for CTC studies.

- Polymorphisms in the following genes: ABCB1, ABCG2, COMT, CYP17, CYP19, CYP1B1, CYP1A1, CYP1A2, CYP2C8, CYP2C9, CYP2J2, CYP3A4, CYP3A5, DPYD, EPHX2, ERalpha, ERbeta, ERCC1, ERCC2, GSTP1, HIF1A, MPO, MTHFR, NQO1, p53, PPARD, SLCO1B3, TYMS, UGT1A1, VEGF, VEGFR, EGFR, SLC28A1, CDA, XRCC1, OCT1, OCT2, CHRNA3 and CHRNA5 will be analyzed by the Clinical Pharmacology Program.

- Methodology for the isolation, enumeration, and live cell culture of CTC with microfiltration devices will be developed by the NCI Genetics Branch.

- Patients will be followed at the medical oncology clinic at the Washington DC VA Medical Center or the NCI and the following information will be recorded in a confidential database: age, gender, race/ethnicity, smoking history, histology, stage, treatment(s) received, response, toxicity, time to disease progression, time to death.

- Associations between genetic polymorphisms and response to therapy, toxicity and clinical outcomes will be analyzed.

- The results of the CTC studies will be applied to the initial development and clinical

validation of CTC technology and lung cancer assays. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT00923884
Study type Observational
Source National Institutes of Health Clinical Center (CC)
Contact
Status Completed
Phase
Start date March 18, 2009
Completion date April 20, 2018

See also
  Status Clinical Trial Phase
Recruiting NCT04486833 - Quaratusugene Ozeplasmid (Reqorsa) and Osimertinib in Patients With Advanced Lung Cancer Who Progressed on Osimertinib Phase 1/Phase 2
Terminated NCT00321308 - Trial of Pemetrexed With or Without PF-3512676 in Advanced Non-Small Cell Lung Cancer Phase 2
Completed NCT00190840 - A Single Arm Phase 2 Study of Pemetrexed as 2nd-Line Treatment of Advanced Non-Small Cell Lung Cancer Phase 2
Terminated NCT01441128 - -02341066 and PF-00299804 for Advanced Non-Small Cell Lung Cancer Phase 1
Recruiting NCT05358249 - Platform Study of JDQ443 in Combinations in Patients With Advanced Solid Tumors Harboring the KRAS G12C Mutation Phase 1/Phase 2
Terminated NCT02961283 - Study of ASN003 in Subjects With Advanced Solid Tumors Phase 1
Recruiting NCT00973310 - Erlotinib Concurrent With Radiation Therapy in Non-small-cell Lung Cancer Phase 2
Completed NCT00385996 - Pilot Study of Preoperative Tarceva (Erlotinib) for Stages I/II Non-Small Cell Lung Cancer Phase 2
Terminated NCT02775006 - Docetaxel Versus Intercalated Erlotinib-docetaxel in Patients With Relapsed EGFR Wild Type, ALK Negative Non Squamous Cell Carcinoma Phase 3
Completed NCT03232593 - A Study of Atezolizumab (Tecentriq®) in Ministry of Food and Drug Safety (MFDS)-Approved Indication(s)
Terminated NCT02590003 - Single Agent Versus Combination Chemotherapy to Treat High-risk Elderly With Non-small Cell Lung Cancer Phase 2
Terminated NCT01514864 - Trial of Dasatinib in Patients With Advanced Cancers Harboring DDR2 Mutation or Inactivating B-RAF Mutation Phase 2
Completed NCT00070629 - CPG 7909 Injection in Non-Small Cell Lung Cancer Phase 2
Completed NCT02079636 - A Study of Abemaciclib (LY2835219) in Combination With Another Anti-cancer Drug in Participants With Lung Cancer (NSCLC) Phase 1
Terminated NCT01115803 - A Study of LY2584702 With Erlotinib or Everolimus in Participants With Solid Tumors Phase 1
Completed NCT01079520 - Endobronchial Ultrasound- Transbronchial Needle Aspiration (EBUS-TBNA) Versus Mediastinoscopy for Mediastinal Lymph Node Staging of Non-small Cell Lung Cancer (NSCLC) N/A
Completed NCT00861627 - Phase 2 Study of REOLYSIN® in Combination With Paclitaxel and Carboplatin for Non-Small Cell Lung Cancer With KRAS or EGFR Activation Phase 2
Recruiting NCT04389632 - A Study of SGN-B6A in Advanced Solid Tumors Phase 1
Terminated NCT03603652 - NEUWAVE Flex Microwave Ablation System in the Ablation of Primary Soft Tissue Lesions of the Lung N/A
Not yet recruiting NCT01131429 - A Chinese Randomized Crossover Study of Erlotinib Versus Docetaxel/Cisplatin in Previously Untreated Stage IIIB/IV Lung Adenocarcinoma With EGFR Mutations Phase 2